Article Text
Abstract
Introduction/Background The aim of this study was to evaluate the impact of lymphovascular space invasion (LVSI) on overall survival (OS) and recurrence-free survival (RFS) in patients treated for epithelial ovarian cancer (EOC).
Methodology Retrospective multicentre study of the research group FRANCOGYN between January 2001 and May 2016. All patients managed for EOC and for whom the presence or absence of LVSI was specified, were included. Patient‘s characteristics with LVSI (LVSI-1) were compared to those without LVSI (LVSI-0). We evaluated the presence of independent risk factors of LVSI. survival analysis were performed in all population and according to frequent pathological subtypes.
Results 493 patients were included. Among them, 164 patients had LVSI (33,3%). More LVSI were observed in advanced stage (p<0,0001), residual disease at the end of surgery (p=0,01), platinum low sensitivity (p=0,03), overall recurrence (p<0,0001), bilateral ovarian involvement (p=0,003), ovarian capsule involvement (p<0,0001), positive peritoneal cytology (p<0,0002), omentum involvement (p<0,0001), pelvic and para-aortic lymph node involvement (p<0,0001). Independent risk factors for LVSI were advanced stage (p<0,001) and ovarian capsule involvement (p<0,001) in multivariate analysis. LVSI affected OS (p<0,0002) and RFS (p<0,0001), OS for early stage (p=0,04) and RFS for advances stage (p=0,007). The related factors to OS were residual disease at the end of surgery (p=0,03), early stage (p=0,0004), presence of LVSI (p=0,04) and pathological type. LVSI and estrogen receptors (ER) affected the RFS of high-grade serous tumors (p=0,0005) with advanced stage (p=0,09) and ER+ (p=0,02) as independent risk factors in multivariate analysis. LVSI affected RFS of endometrioid tumors (p=0,006) and low-grade serous tumors (p=0,018) as well as OS and RFS of mucinous tumors (p<0,0001).
Conclusion LVSI in EOC has an impact on OS and RFS. It can be considered as a major prognostic factor to consider in patients with ovarian cancer.
Disclosure Nothing to disclose.